(1 - 8 from 10
)
Mayne first to offer Medsaic's DotScan as leukaemia test
www.labonline.com.au
"It's an important event for us, to have our first customer over the line, and a customer with the calibre of Mayne," said Medsaic's CEO Jeremy Chrisp. Medsaic -- a spin-off from the University of Sydney -- placed its first-generation scanner and test kits with Mayne Health in November 2002, said Chrisp.
New board appointments for EpiAxis The…utics - Biotechbiotechdispatch.com.au › news › new-board-appointments-for-epiaxis-ther...
30 Jul · ... that underline our belief that we can become the leader in the epigenetic control of metastatic cancer.” said EpiAxis CEO Dr Jeremy Chrisp.
WarraPharm to commer…e colorectal cancer therapy - Newsmakerwww.newsmaker.com.au › news › warrapharm-to-commer…e-colorectal...
9 Nov · ... chemothe…utic regimen that patients can tolerate over repeated treatment cycles,” said WarraPharm CEO, Dr Jeremy Chrisp. “With our ...
Treffen von Spitzenvertretern der Arzneimittelentwicklung aus der...
www.prnewswire.com
In der Kategorie „Bestes Verkaufsgespräch" ging der zweite Platz an Jeremy Chrisp, CEO von EpiAxis The…utics, und der dritte Platz an ...
sorted by relevance / date